Key result
Distinct white adipocyte subpopulations may play different roles in obesity-associated T2DM, NAFLD, and CVD.
Why the study?
Distinct white adipocyte subpopulations in white adipose tissue and their alterations with adiposity and metabolic disease are not fully understood.
Understanding white adipocyte heterogeneity and its role in metabolic disease could provide novel therapeutic targets for T2DM, NAFLD, and cardiovascular disease.
Answers are grounded in this paper and cite their sources.
Adipocyte subpopulation shifts may link obesity to cardiometabolic risk; leaves open whether targeting heterogeneity alters disease progression.
PURPOSE OF REVIEW: This review aims to discuss the most recent evidence identifying the presence of distinct white adipocyte subpopulations in white adipose tissue (WAT) and how these may be altered with increasing adiposity and/or metabolic disease. We conceptualize how changes in adipocyte subpopulations may contribute to alterations in WAT function and the development of metabolic diseases such as type 2 diabetes mellitus (T2DM), nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD). RECENT FINDINGS: Studies utilizing novel analytical approaches support the existence of distinct white adipocyte subpopulations in both human and murine WAT. Adipocyte subtypes are potentially functionally distinct and may have different roles in WAT function and obesity-associated metabolic diseases. SUMMARY: The exploration of white adipocyte heterogeneity using novel analytical technologies, has unveiled a new layer of complexity in the study of WAT biology. Interrogation of potential functional differences between adipocyte subpopulations and their role in the function of different WAT depots is now needed. Through understanding the mechanisms regulating white adipocyte subtype development and potential pathophysiological consequences of changes in the presence of adipocyte subpopulations, studies could provide novel therapeutic targets for the treatment of T2DM, NAFLD, and CVD.
No takes yet. Share an insight, caveat, or question.
Bilson et al. (2023) conducted a review in Metabolic disease (T2DM, NAFLD, CVD). White adipocyte heterogeneity was evaluated. Distinct white adipocyte subpopulations exist in human and murine white adipose tissue and may play different roles in obesity-associated metabolic diseases like T2DM, NAFLD, and CVD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: